Adherence with Migraine Prophylaxis in Clinical Practice

Pain Practice

Volumn 12, Issue 7, 2012, Pages 541-549

  Berger, Ariel ^a   Bloudek, Lisa M ^b   Varon, Sepideh F ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Drug therapy; Drug utilization; Migraine disorders; Migraine headache; Prophylaxis

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; METOPROLOL; MIRTAZAPINE; NADOLOL; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROPRANOLOL; PROTRIPTYLINE; SERTRALINE; TIMOLOL; TOPIRAMATE; TRAZODONE; VALPROATE SEMISODIUM; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL PRACTICE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION PROGRESSION RATIO; MIGRAINE; PARAMETERS; PATIENT COMPLIANCE; PRESCRIPTION; PROPHYLAXIS;

EID: 84865964987     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2012.00530.x     Document Type: Article

References (38)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349.
2. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559.
3. Insinga RP, Ng-Mak DS, Hanson ME. Associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalalgia. 2011;31:1570-1575.
4. Gibbs TS, Fleischer AB Jr, Feldman SR, Sam MC, O'Donovan CA. Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache. 2003;43:330-335.
5. Negro A, D'Alonzo L, Martelletti P. Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med. 2010;5(Suppl 1):S13-S19.
6. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9:391-401.
7. Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. 2010;341:c4871. DOI:10.1136/bmj.c4871.
8. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002;42:510-514.
9. Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010;341:c5222.
10. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48:210-220.
11. Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61:1753-1759.
12. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-823.
13. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490-495.
14. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793-803.
15. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-814.
16. Dodick DW, Turkel CC, Degryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921-936.
17. ® (topiramate capsules) Sprinkle Capsule Prescribing Information. Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2009.
18. ® LA (propranolol hydrochloride) Long-Acting Capsules. Prescribing Information. Wyeth Pharmaceuticals Inc; 2008.
19. BOTOX® (onabotulinumtoxinA). Prescribing Information. Allergan, Inc; 2010.
20. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638-645.
21. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15:70-78.
22. Silberstein SD, Feliu AL, Rupnow MFT, Blount AC, Boccuzzi SJ. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache. 2007;47:500-510.
23. Stang PE, Crown WE, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. Am J Manag Care. 2004;10:313-320.
24. Lafata JE, Moon C, Leotta C, Kolodner K, Poisson L, Lipton RB. The medical care utilization and costs associated with migraine headache. J Gen Intern Med. 2004;19:1005-1012.
25. Sikka R, Xia F, Aubert RE. Estimating medication adherence using administrative claims data. Am J Manag Care. 2005;11:449-457.
26. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303-2310.
27. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for healthcare costs. Clin Ther. 1997;19:1446-1457.
28. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16:568-576.
29. Gosselin A, Luo R, Lohoues H, et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health. 2009;12:34-39.
30. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17:25-39.
31. Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25:1711-1719.
32. Zivin K, Ganoczy D, Pfeiffer PN, Miller EM, Valenstein M. Antidepressant adherence after psychiatric hospitalization among VA patients with depression. Adm Policy Ment Health. 2009;36:406-415.
33. Stang P, Suppapanaya N, Hogue SL, Park D, Rigney U. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Am J Ther. 2007;14:241-246.
34. McLaughlin T, Hogue SL, Stang P. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. Am J Ther. 2007;14:221-225.
35. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44:300-303.
36. Keene MS, Eaddy MT, Mauch RP, Regan TS, Shah M, Chiao E. Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs). Curr Med Res Opin. 2005;21:1651-1658.
37. Kalsekar ID, Madhavan SS, Amonkar MM, et al. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents. Ann Pharmacother. 2006;40:605-611.
38. Kreynbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophr Bull. 2010;36:428-435.